CN109602737B - 羟基红花黄色素b在制备治疗胃癌药物中的应用及药物 - Google Patents
羟基红花黄色素b在制备治疗胃癌药物中的应用及药物 Download PDFInfo
- Publication number
- CN109602737B CN109602737B CN201910071586.3A CN201910071586A CN109602737B CN 109602737 B CN109602737 B CN 109602737B CN 201910071586 A CN201910071586 A CN 201910071586A CN 109602737 B CN109602737 B CN 109602737B
- Authority
- CN
- China
- Prior art keywords
- gastric cancer
- medicine
- hydroxysafflor yellow
- hsyb
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 70
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 70
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 70
- 229930195259 hydroxysafflor yellow Natural products 0.000 title claims abstract description 35
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title description 6
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000002775 capsule Substances 0.000 abstract description 4
- 239000008187 granular material Substances 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 4
- 239000006187 pill Substances 0.000 abstract description 4
- 239000007901 soft capsule Substances 0.000 abstract description 4
- 239000006188 syrup Substances 0.000 abstract description 4
- 235000020357 syrup Nutrition 0.000 abstract description 4
- 239000003826 tablet Substances 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 24
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 230000022131 cell cycle Effects 0.000 description 15
- 238000001262 western blot Methods 0.000 description 9
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical compound O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 238000011002 quantification Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 102000016736 Cyclin Human genes 0.000 description 5
- 108050006400 Cyclin Proteins 0.000 description 5
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 5
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 5
- 230000018199 S phase Effects 0.000 description 5
- 101150073031 cdk2 gene Proteins 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 102100025191 Cyclin-A2 Human genes 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 108091007914 CDKs Proteins 0.000 description 3
- 108010060273 Cyclin A2 Proteins 0.000 description 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000025084 cell cycle arrest Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- -1 flavanone compound Chemical class 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012160 loading buffer Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000010413 mother solution Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- IAVUBSCVWHLRGE-UXEKTNMQSA-N (6e)-2,5-dihydroxy-6-[(e)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C(C(C(O)([C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C1=O)=O)=C(O)\C1=C(/O)\C=C\C1=CC=C(O)C=C1 IAVUBSCVWHLRGE-UXEKTNMQSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 101000577520 Chlamydomonas reinhardtii Photosystem I reaction center subunit III, chloroplastic Proteins 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000012824 ERK inhibitor Substances 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102100037858 G1/S-specific cyclin-E1 Human genes 0.000 description 1
- 206010060850 Gastric adenoma Diseases 0.000 description 1
- 101000738568 Homo sapiens G1/S-specific cyclin-E1 Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- ZZMASNSDVDSYKO-UHFFFAOYSA-N hydroxysafflor yellow A Natural products OCC1OC(C(O)C(O)C1O)C2=C(O)C(O)(C3OC(CO)C(O)C(O)C3O)C(=O)C(=C2O)C(=O)C=Cc4ccc(O)cc4 ZZMASNSDVDSYKO-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- KINGXFAMZNIVNL-SXQDSXCISA-N safflor yellow A Natural products OC[C@@H]1O[C@H]2[C@H](OC3=C2C(=O)C(=C(O)C=Cc4ccc(O)cc4)C(=O)[C@]3(O)[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H]1O KINGXFAMZNIVNL-SXQDSXCISA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910071586.3A CN109602737B (zh) | 2019-01-25 | 2019-01-25 | 羟基红花黄色素b在制备治疗胃癌药物中的应用及药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910071586.3A CN109602737B (zh) | 2019-01-25 | 2019-01-25 | 羟基红花黄色素b在制备治疗胃癌药物中的应用及药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109602737A CN109602737A (zh) | 2019-04-12 |
CN109602737B true CN109602737B (zh) | 2021-02-19 |
Family
ID=66019303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910071586.3A Active CN109602737B (zh) | 2019-01-25 | 2019-01-25 | 羟基红花黄色素b在制备治疗胃癌药物中的应用及药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109602737B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101190906A (zh) * | 2007-06-22 | 2008-06-04 | 北京星昊医药股份有限公司 | 红花黄色素b的制备方法及其应用 |
CN106083788A (zh) * | 2016-06-24 | 2016-11-09 | 南京中医药大学 | 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10336788B2 (en) * | 2014-04-17 | 2019-07-02 | Moerae Matrix, Inc. | Inhibition of cardiac fibrosis in myocardial infarction |
-
2019
- 2019-01-25 CN CN201910071586.3A patent/CN109602737B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101190906A (zh) * | 2007-06-22 | 2008-06-04 | 北京星昊医药股份有限公司 | 红花黄色素b的制备方法及其应用 |
CN106083788A (zh) * | 2016-06-24 | 2016-11-09 | 南京中医药大学 | 一种具有抗肿瘤活性和抗炎活性的醌式查尔酮碳苷二聚体化合物及其制备方法 |
Non-Patent Citations (4)
Title |
---|
Research progress on the antioxidant therapy for gastric cancer;Lina Yu et al.;《Journal of Chinese Pharmaceutical Sciences》;20160407;第25卷(第6期);摘要 * |
Shijun Yue 等.Two New Quinochalcone C-Glycosides from the Florets of Carthamus tinctorius.《International Journal of Molecular Sciences》.2014,第15卷16760-16771页. * |
Two New Quinochalcone C-Glycosides from the Florets of Carthamus tinctorius;Shijun Yue 等;《International Journal of Molecular Sciences》;20141231;第15卷;图4 * |
羟基红花黄色素A对体外培养人胃癌细胞增殖、凋亡及周期的影响;王景景等;《中华中医药杂志(原中国医药学报)》;20160930;第31卷(第9期);第3740页右栏 * |
Also Published As
Publication number | Publication date |
---|---|
CN109602737A (zh) | 2019-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Luo et al. | Ursolic acid inhibits breast cancer growth by inhibiting proliferation, inducing autophagy and apoptosis, and suppressing inflammatory responses via the PI3K/AKT and NF‑κB signaling pathways in vitro | |
Guan et al. | Salidroside attenuates LPS-induced pro-inflammatory cytokine responses and improves survival in murine endotoxemia | |
Yang et al. | Mitophagy: A crucial modulator in the pathogenesis of chronic diseases | |
Li et al. | Baicalin, a component of Scutellaria baicalensis, alleviates anorexia and inhibits skeletal muscle atrophy in experimental cancer cachexia | |
Park et al. | Anti-tumor effects of jaceosidin on apoptosis, autophagy, and necroptosis in human glioblastoma multiforme | |
Huang et al. | Sinapic acid inhibits pancreatic cancer proliferation, migration, and invasion via downregulation of the AKT/Gsk‐3β signal pathway | |
Qu et al. | Polysaccharides derived from Balanophora polyandra significantly suppressed the proliferation of ovarian cancer cells through P53‐mediated pathway | |
Chen et al. | Extracts derived from a traditional Chinese herbal formula triggers necroptosis in ectocervical Ect1/E6E7 cells through activation of RIP1 kinase | |
CN113491685B (zh) | 一种抑制巨噬细胞活化的组合物及其在制备抗炎制品中的应用 | |
Zhang et al. | Cudraxanthone L inhibits gastric cancer by regulating the MAPK signalling and promoting FAS-mediated pathway | |
CN109602737B (zh) | 羟基红花黄色素b在制备治疗胃癌药物中的应用及药物 | |
CN104817608B (zh) | 含硒化合物的虫草素盐及其制备方法和用途 | |
Liu et al. | Paiteling induces apoptosis of cervical cancer cells by down-regulation of the E6/E7-Pi3k/Akt pathway: A network pharmacology | |
Li et al. | Effect of procyanidins from Pinus koraiensis bark on growth inhibition and expression of PCNA and TNF-[alpha][alpha] in mice with U14 cervical cancer | |
CN110876741B (zh) | 一种gbe1抑制剂夫拉平度及其药物组合物在制备治疗肺腺癌药物中的应用 | |
CN109223801B (zh) | 一种新的胃癌肿瘤干细胞杀伤剂及其应用 | |
JP7152052B2 (ja) | カリマイシン又はその活性成分の用途 | |
CN108392530B (zh) | 黄芩汤及其等效成分群用于增强结肠癌对伊立替康化疗敏感性的用途 | |
CN111000850A (zh) | 隐丹参酮在制备克服nsclc治疗药物egfr-tki耐药的药物中的应用 | |
CN108619145B (zh) | 化合物在治疗肿瘤中的应用 | |
CN107260752B (zh) | 一种协同抗胰腺癌的药物组合物 | |
CN110776542A (zh) | 一种从金花茶提取的化合物及其制备抗肿瘤药物应用 | |
CN116617359B (zh) | 王不留行环肽b在制备治疗前列腺肿瘤药物中的应用 | |
CN117752714A (zh) | 一种黄堇乙醇提取物及其制备方法与应用 | |
CN107684563B (zh) | 一种含有美洲大蠊和伊马替尼的药物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Application and application of hydroxysafflower yellow B in the preparation of drugs for the treatment of gastric cancer Effective date of registration: 20211214 Granted publication date: 20210219 Pledgee: Yantai financing guarantee Group Co.,Ltd. Pledgor: BINZHOU MEDICAL University Registration number: Y2021980014859 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210219 Pledgee: Yantai financing guarantee Group Co.,Ltd. Pledgor: BINZHOU MEDICAL University Registration number: Y2021980014859 |